trial

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I

NCTId NCT02811939
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 13 (actual)
Sponsored by Yale University
Primary completion 2017-06-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
13 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2016-04-07
Primary completion
2017-06-09
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Active DronabinolActive Pregnenolone

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Deepak Cyril D'Souza, MDPrincipal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
13
Phase
PHASE1
Primary Completion Date
2017-06-09
Status
COMPLETED
relationships
The graph out of here
drug
Active Dronabinol
drug
Active Pregnenolone
drug
lead_sponsor
Yale University
company
indication
Psychotic Disorders
indication
Healthy
indication
Marijuana Abuse
indication
investigator
Deepak Cyril D'Souza, MD
person